Non-Vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in Denmark

L. Staerk, E L Fosbøl, K. Gadsbøll, Caroline Sindet-Pedersen, J. L. Pallisgaard, M. Lamberts, Gregory Y H Lip, C. Torp-Pedersen, G. H. Gislason, J. B. Olesen

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

    169 Downloads (Pure)


    Among atrial fibrillation (AF) patients, Danish nationwide registries (2011-2015) were used to examine temporal trends of initiation patterns of oral anticoagulation (OAC) treatment according to age. Overall, 43,299 AF patients initiating vitamin K antagonists (VKA) (42%), dabigatran (29%), rivaroxaban (13%), or apixaban (16%) were included with mean age (SD) 72.1 (11.3), 71.5 (11.0), 74.3 (11.1), and 75.3 (11.1) years, respectively. Patients aged ≥85 years comprised 15%. Trend tests showed increase in patients ≥85 years initiating OAC (p <0.0001). VKA usage decreased from 92% to 24% (p <0.0001). This decrease was independent of age. Dabigatran was the most common non-VKA OAC (NOAC) (40% users), but usage decreased from 2014 until study end (6%) (p <0.0001). Apixaban was the most used OAC at study end (41%), in particular among those ≥85 years (44%). Compared with patients aged
    TidsskriftScientific Reports
    Antal sider9
    StatusUdgivet - 2016